Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.25.0.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 07, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-37348    
Entity Registrant Name Corbus Pharmaceuticals Holdings, Inc.    
Entity Central Index Key 0001595097    
Entity Tax Identification Number 46-4348039    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 500 River Ridge Drive    
Entity Address, City or Town Norwood    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02062    
City Area Code 617    
Local Phone Number 963-0100    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol CRBP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 428.0
Entity Common Stock, Shares Outstanding   12,232,228  
ICFR Auditor Attestation Flag false    
Documents Incorporated by Reference

None.

    
Auditor Firm ID 274    
Auditor Location Iselin, New Jersey    
Auditor Name EISNERAMPER LLP    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Corbus Pharmaceuticals Holdings, Inc. and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of their operations and their cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.